Study guide

5.3 Vasoactive & Inotropic Medication Titration

IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics

2 Chapter 2: Transport and Safety (Part 1)

2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols

3 Chapter 2: Transport and Safety (Part 2)

2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations

4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)

3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes

5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)

3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation

6 Chapter 4: General Medical Patient

4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport

7 Chapter 5: Cardiac Patient

5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care

8 Chapter 6: Neurological Patient

6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

9 Chapter 7: Respiratory Patient

7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds

10 Chapter 8: Toxic Exposure and Environmental Patient

8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat

11 Chapter 9: Trauma and Burn Patient

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome

12 Chapter 10: Maternal and Fetal Medicine

10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring

13 Chapter 11: Pediatric Patient

11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate

14 Chapter 12: Special Populations

12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology

15 Chapter 13: Professional Considerations

13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice

5.3 Vasoactive & Inotropic Medication Titration

Key Takeaways Explain This Topic AI

Vasoactive medications target specific adrenergic (Alpha-1, Beta-1, Beta-2), dopaminergic (D1), and vasopressinergic (V1a) receptors to modulate vascular tone and cardiac contractility.

Norepinephrine is the first-line vasopressor for septic and cardiogenic shock due to potent Alpha-1 vasoconstriction with moderate Beta-1 inotropic support.

Dopamine exhibits dose-dependent receptor selectivity: low dose (0.5-3 mcg/kg/min) targets D1, medium dose (3-10 mcg/kg/min) targets Beta-1, and high dose (10-20 mcg/kg/min) targets Alpha-1.

Milrinone (PDE3 inhibitor) and Dobutamine (Beta-1 agonist) provide inotropic support; Milrinone causes non-adrenergic vasodilation without increasing oxygen demand via beta pathways.

Sodium Nitroprusside requires light protection and carries high risks of cyanide and thiocyanate toxicity, presenting as metabolic acidosis with elevated SvO2.

Last updated: July 2026

5.3 Vasoactive & Inotropic Medication Titration

In critical care transport, precise titration of vasoactive and inotropic continuous infusions is vital for restoring tissue perfusion and stabilizing hemodynamics. Understanding receptor pharmacology, cellular mechanisms of action, infusion kinetics, potential toxicities, and concentration conversion formulas is required to prevent life-threatening under- or over-dosing.

Receptor Pharmacology Overview

Vasoactive drugs exert clinical actions by binding to specific G-protein-coupled membrane receptors on cardiac myocytes and vascular smooth muscle: RECEPTOR TARGETS & CELLULAR RESPONSES:

  • ┌──────────┬─────────────────────────────────────┬──────────────────────────────────────────┐
  • │ Receptor │ Primary Location │ Physiological Response │
  • ├──────────┼─────────────────────────────────────┼──────────────────────────────────────────┤
  • │ Alpha-1 │ Vascular Smooth Muscle │ Vasoconstriction -> Increased SVR & MAP │
  • │ Beta-1 │ Cardiac Myocytes & SA/AV Nodes │ Inotropy (+Contractility) & Chronotropy │
  • │ Beta-2 │ Vascular & Bronchial Smooth Muscle │ Vasodilation & Bronchodilation │
  • │ Dopamine │ Renal & Splanchnic Vasculature │ Renal & Splanchnic Vasodilation (D1) │
  • │ V1a │ Vascular Smooth Muscle │ Non-adrenergic Vasoconstriction │
  • └──────────┴─────────────────────────────────────┴──────────────────────────────────────────┘

α 1 \alpha_1 α 1 ​ Adrenergic : Coupled to G q G_q G q ​ proteins. Activation increases intracellular calcium ( I P 3 / D A G IP_3/DAG I P 3 ​ / D A G pathway), triggering potent vasoconstriction of arterial and venous smooth muscle.

β 1 \beta_1 β 1 ​ Adrenergic : Coupled to G s G_s G s ​ proteins. Activation stimulates adenylyl cyclase, raising cyclic adenosine monophosphate (cAMP) and intracellular calcium. This yields positive inotropy (contractility), positive chronotropy (heart rate), positive dromotropy (conduction speed), and positive lusitropy (ventricular relaxation).

β 2 \beta_2 β 2 ​ Adrenergic : Coupled to G s G_s G s ​ proteins in vascular and bronchial smooth muscle. Upregulation of cAMP leads to calcium efflux, causing vasodilation and bronchodilation .

Dopaminergic ( D 1 D_1 D 1 ​ ) : Coupled to G s G_s G s ​ proteins in renal, mesenteric, coronary, and cerebral vascular beds, promoting vasodilation.

Vasopressin ( V 1 a V_{1a} V 1 a ​ ) : Coupled to G q G_q G q ​ proteins on vascular smooth muscle. Activation causes direct calcium release and intense vasoconstriction , operating independently of adrenergic receptors.

  • Comprehensive Vasoactive & Inotropic Drug Profiles
  • 1. Norepinephrine (Levophed)

Receptor Profile : Potent α 1 \alpha_1 α 1 ​ agonist with moderate β 1 \beta_1 β 1 ​ agonist activity ( α 1 + + + + , β 1 + + \alpha_1 ++++, \beta_1 ++ α 1 ​ + + + + , β 1 ​ + + ).

Hemodynamic Effects : Marked systemic vasoconstriction leading to increased SVR and MAP, accompanied by modest inotropic support. Reflex bradycardia often offsets β 1 \beta_1 β 1 ​ chronotropic effects.

Clinical Indications : First-line vasopressor for septic shock , cardiogenic shock (in combination with Dobutamine), and neurogenic shock .

Dosing & Titration : Initial 0.02 - 0.05 mcg/kg/min (or 2 − 5 mcg/min 2 - 5\text{ mcg/min} 2 − 5 mcg/min ), titrated by 0.02 − 0.05 mcg/kg/min 0.02-0.05\text{ mcg/kg/min} 0.02 − 0.05 mcg/kg/min every 2-5 minutes to target MAP ≥ 65 mmHg \text{MAP} \ge 65\text{ mmHg} MAP ≥ 65 mmHg . Standard concentration: 4 mg 4\text{ mg} 4 mg in 250 mL 250\text{ mL} 250 mL D5W or NS ( 16 mcg/mL 16\text{ mcg/mL} 16 mcg/mL ).

2. Epinephrine (Adrenalin)

Receptor Profile : Potent agonist across β 1 \beta_1 β 1 ​ , β 2 \beta_2 β 2 ​ , and α 1 \alpha_1 α 1 ​ receptors.

Dose-Dependent Receptor Transitions :

Low Dose ( 0.01 − 0.05 mcg/kg/min 0.01 - 0.05\text{ mcg/kg/min} 0.01 − 0.05 mcg/kg/min ) : Predominant β 1 \beta_1 β 1 ​ and β 2 \beta_2 β 2 ​ stimulation. Increases cardiac output and heart rate while causing mild peripheral vasodilation.

High Dose ( > 0.1 mcg/kg/min > 0.1\text{ mcg/kg/min} > 0.1 mcg/kg/min ) : α 1 \alpha_1 α 1 ​ effects predominate, causing profound systemic vasoconstriction and elevation of MAP.

Clinical Indications : First-line in anaphylactic shock , cardiac arrest , post-cardiac arrest shock , and severe symptomatic bradycardia refractory to atropine.

Metabolic Signatures : Epinephrine stimulates hepatic glycogenolysis and skeletal muscle β 2 \beta_2 β 2 ​ -receptor Na+/K+-ATPase pumps, causing transient hyperlactatemia and hyperglycemia without tissue hypoxia.

Dosing : Continuous infusion 0.01 - 0.5 mcg/kg/min titrated to hemodynamic effect.

3. Dopamine

Receptor Profile : Precursor to norepinephrine exhibiting distinct dose-dependent receptor affinity: DOPAMINE DOSE-DEPENDENT RECEPTOR SPECTRUM:

  • 0.5 - 3.0 mcg/kg/min ===> D1 Receptor ---> Renal & Splanchnic Vasodilation
  • 3.0 - 10.0 mcg/kg/min ===> Beta-1 Receptor ---> Increased Contractility & HR
  • 10.0 - 20.0 mcg/kg/min ===> Alpha-1 Receptor ---> Systemic Vasoconstriction

Clinical Considerations : Dopamine triggers significant endogenous norepinephrine release. It carries high risks of tachyarrhythmias (atrial fibrillation, VT) compared to Norepinephrine. Low-dose "renal dose" dopamine does NOT provide renal protection or prevent acute kidney injury and is no longer recommended.

4. Phenylephrine (Neo-Synephrine)

Receptor Profile : Pure, selective α 1 \alpha_1 α 1 ​ agonist ( α 1 + + + + \alpha_1 ++++ α 1 ​ + + + + , no β \beta β activity).

Hemodynamic Effects : Produces arterial vasoconstriction, raising SVR and MAP without direct cardiac inotropic or chronotropic stimulation. Induces reflex bradycardia and can decrease stroke volume in patients with baseline LV dysfunction.

Clinical Indications : Hyperdynamic septic shock with severe tachycardia, anesthesia-induced hypotension, or neurogenic shock.

Dosing : 0.5 - 5.0 mcg/kg/min (or 20 − 200 mcg/min 20 - 200\text{ mcg/min} 20 − 200 mcg/min ).

5. Vasopressin (Pitressin)

Receptor Profile : Selective V 1 a V_{1a} V 1 a ​ receptor agonist .

Hemodynamic Effects : Direct vascular smooth muscle vasoconstriction. Operates effectively in severe acidosis and catecholamine-refractory shock where adrenergic receptors are desensitized.

Clinical Indications : Adjuvant vasopressor in septic shock to reduce norepinephrine dosage requirements ("norepinephrine-sparing effect") and in vasodilatory shock.

Dosing : Administered as a fixed, non-titrated infusion of 0.03 units/min (or 0.01 − 0.04 units/min 0.01-0.04\text{ units/min} 0.01 − 0.04 units/min ). Never titrate rapidly due to risks of intestinal and myocardial ischemia.

6. Dobutamine (Dobutrex)

Receptor Profile : Synthetic catecholamine with potent β 1 \beta_1 β 1 ​ agonist and mild β 2 \beta_2 β 2 ​ agonist activity ( β 1 + + + + , β 2 + + \beta_1 ++++, \beta_2 ++ β 1 ​ + + + + , β 2 ​ + + ).

Hemodynamic Effects : Significant positive inotropy and chronotropy with mild vascular smooth muscle dilation. Increases Cardiac Output and Stroke Volume while reducing PAWP and SVR.

Clinical Indications : Severe decompensated heart failure and cardiogenic shock (often paired with Norepinephrine to offset vasodilation).

Dosing : 2.5 - 20.0 mcg/kg/min .

7. Milrinone (Primacor)

Receptor Profile : Non-adrenergic Phosphodiesterase-3 (PDE3) Inhibitor .

Mechanism of Action : Inhibits PDE3 enzymes in cardiac myocytes and vascular smooth muscle, preventing breakdown of cyclic AMP (cAMP). High cAMP levels increase intracellular calcium in myocytes (enhancing contractility) while accelerating calcium uptake in vascular smooth muscle (causing relaxation).

Hemodynamic Effects : Known as an "Inodilator" . Increases Cardiac Index while markedly reducing PAWP, CVP, SVR, and Pulmonary Vascular Resistance (PVR). Does not increase myocardial oxygen consumption to the same extent as beta-agonists.

Elimination & Kinetics : Renally eliminated with a long elimination half-life ( 2 − 4 hours 2 - 4\text{ hours} 2 − 4 hours ). Requires dose reductions in renal failure ( C r C l < 50 mL/min CrCl < 50\text{ mL/min} C r Cl < 50 mL/min ). IV loading boluses ( 50 mcg/kg 50\text{ mcg/kg} 50 mcg/kg ) are typically omitted in critical transport to prevent sudden hypotension.

Dosing : Continuous infusion 0.125 - 0.75 mcg/kg/min .

8. Sodium Nitroprusside (Nipride)

Mechanism of Action : Direct nitric oxide (NO) donor causing immediate relaxation of vascular smooth muscle in both arteries and veins.

Hemodynamic Effects : Balanced arterial and venous vasodilation. Decreases SVR (afterload) and PAWP/CVP (preload), reducing cardiac workload.

Clinical Indications : Hypertensive emergencies, acute aortic dissection, and acute mitral regurgitation.

Cyanide & Thiocyanate Toxicity Risks :

Sodium Nitroprusside contains five cyanide groups per molecule. Metabolism by hemoglobin releases free cyanide.

Cyanide Toxicity : Free cyanide binds to ferric iron ( F e 3 + Fe^{3+} F e 3 + ) in mitochondrial cytochrome oxidase, shutting down oxidative phosphorylation and cellular respiration. Presents as unexplained metabolic acidosis , elevated serum lactate, and elevated SvO2 (cells cannot extract oxygen). Treatment: Hydroxocobalamin (Cyanokit) or Sodium Thiosulfate.

Thiocyanate Toxicity : Occurs during prolonged infusions ( > 48 hours > 48\text{ hours} > 48 hours ) or renal impairment. Presents with confusion, hyperreflexia, tinnitus, and seizures.

Administration Rule : Must be protected from light using amber light-blocking sleeves.

Dosing : 0.25 - 10.0 mcg/kg/min .

9. Nitroglycerin (Tridil)

Mechanism of Action : Direct nitric oxide donor acting primarily on venous capacitance vessels at lower doses ( < 50 mcg/min < 50\text{ mcg/min} < 50 mcg/min ) to reduce preload (PAWP/CVP). At higher doses ( > 100 − 200 mcg/min > 100-200\text{ mcg/min} > 100 − 200 mcg/min ), causes arterial vasodilation, reducing afterload.

Clinical Indications : Acute Coronary Syndromes, acute cardiogenic pulmonary edema, and hypertensive crisis.

Special Considerations : Requires non-PVC glass or polyethylene IV tubing to prevent drug adsorption into plastic matrix. Tachyphylaxis (tolerance) develops within 24-48 hours.

Dosing : 5 - 200 mcg/min .

Infusion Calculation Formulas & Conversions

Critical care paramedics must execute rapid, error-free drug concentration and infusion rate calculations.

1. Concentration Formula Concentration (mcg/mL) = Total Drug Amount (mg) × 1000 mcg/mg Total Volume (mL) \text{Concentration (mcg/mL)} = \frac{\text{Total Drug Amount (mg)} \times 1000\text{ mcg/mg}}{\text{Total Volume (mL)}} Concentration (mcg/mL) = Total Volume (mL) Total Drug Amount (mg) × 1000 mcg/mg ​

Example : 4 mg 4\text{ mg} 4 mg Norepinephrine in 250 mL 250\text{ mL} 250 mL D5W = 4000 mcg 250 mL = 16 mcg/mL = \frac{4000\text{ mcg}}{250\text{ mL}} = 16\text{ mcg/mL} = 250 mL 4000 mcg ​ = 16 mcg/mL .

2. Weight-Based Infusion Rate Formula (mL/hr) Rate (mL/hr) = Dose (mcg/kg/min) × Weight (kg) × 60 min/hr Concentration (mcg/mL) \text{Rate (mL/hr)} = \frac{\text{Dose (mcg/kg/min)} \times \text{Weight (kg)} \times 60\text{ min/hr}}{\text{Concentration (mcg/mL)}} Rate (mL/hr) = Concentration (mcg/mL) Dose (mcg/kg/min) × Weight (kg) × 60 min/hr ​

Worked Calculation Example :

Patient weight = 80 kg = 80\text{ kg} = 80 kg . Ordered dose = 0.1 mcg/kg/min = 0.1\text{ mcg/kg/min} = 0.1 mcg/kg/min Norepinephrine. Concentration = 16 mcg/mL = 16\text{ mcg/mL} = 16 mcg/mL . Rate = 0.1 mcg/kg/min × 80 kg × 60 min/hr 16 mcg/mL = 480 mcg/hr 16 mcg/mL = 30 mL/hr \text{Rate} = \frac{0.1\text{ mcg/kg/min} \times 80\text{ kg} \times 60\text{ min/hr}}{16\text{ mcg/mL}} = \frac{480\text{ mcg/hr}}{16\text{ mcg/mL}} = 30\text{ mL/hr} Rate = 16 mcg/mL 0.1 mcg/kg/min × 80 kg × 60 min/hr ​ = 16 mcg/mL 480 mcg/hr ​ = 30 mL/hr

3. Non-Weight-Based Infusion Rate Formula (mL/hr) Rate (mL/hr) = Dose (mcg/min) × 60 min/hr Concentration (mcg/mL) \text{Rate (mL/hr)} = \frac{\text{Dose (mcg/min)} \times 60\text{ min/hr}}{\text{Concentration (mcg/mL)}} Rate (mL/hr) = Concentration (mcg/mL) Dose (mcg/min) × 60 min/hr ​

Worked Calculation Example :

Ordered dose = 40 mcg/min = 40\text{ mcg/min} = 40 mcg/min Nitroglycerin. Concentration = 50 mg = 50\text{ mg} = 50 mg in 250 mL 250\text{ mL} 250 mL ( 200 mcg/mL 200\text{ mcg/mL} 200 mcg/mL ). Rate = 40 mcg/min × 60 min/hr 200 mcg/mL = 2400 mcg/hr 200 mcg/mL = 12 mL/hr \text{Rate} = \frac{40\text{ mcg/min} \times 60\text{ min/hr}}{200\text{ mcg/mL}} = \frac{2400\text{ mcg/hr}}{200\text{ mcg/mL}} = 12\text{ mL/hr} Rate = 200 mcg/mL 40 mcg/min × 60 min/hr ​ = 200 mcg/mL 2400 mcg/hr ​ = 12 mL/hr